Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.89 |
| ▸ | EDNRB | P24530 | 18/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | TSPO | P30536 | 1/20 | 0.89 |
| ▸ | DRD3 | P35462 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Macitentan SCHEMBL29378853 | 0.94 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Macitentan SCHEMBL1445625 | 0.94 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569156 | 0.93 | EDNRA (0.89) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569102 | 0.92 | EDNRA (0.88) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL23876322 | 0.91 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380521 | 0.91 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380524 | 0.90 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380505 | 0.89 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL18330569 | 0.88 | EDNRA (0.81) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380529 | 0.88 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648249-B2 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | ACTELION PHARMACEUTICALS LTD (CH) | 2023-05-16 | — | — | US | disclosed |
| US-11649216-B2 | Method for preparing Macitentan and intermediate compound thereof | Seasons Biotechnology (Taizhou) Co., Ltd. (CN) | 2023-05-16 | — | — | US | disclosed |
| WO-2017191565-A1 | PROCESS FOR PREPARATION OF MACITENTAN | SHILPA MEDICARE LIMITED (IN) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649216-B2 | Method for preparing Macitentan and intermediate compound thereof | TPMT, NUDT1, DHPS | EDNRA 4090/4885EDNRB 3570/4885SLC6A2 1379/4885 |
| US-11648249-B2 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | DPYD, TYMS, TYMP | EDNRA 4280/4885EDNRB 4071/4885SLC6A2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.